Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment
NCT ID: NCT05225155
Last Updated: 2022-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
104 participants
OBSERVATIONAL
2015-02-02
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medical Assistance for the Procreation and Risk of Thrombosis.
NCT02610608
Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
NCT01068795
Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial
NCT02600260
Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
NCT00878826
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
NCT01729559
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Women without thrombophilia, submitted to in vitro fertilization techniques
No interventions assigned to this group
Untreated Thrombophilia
Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin
No interventions assigned to this group
Treated Thrombophilia
Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin
Enoxaparin
Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enoxaparin
Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal sperm analysis
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Faculdade de Medicina do ABC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luciano de Melo Pompei'
Auxiliary Professor at Gynecology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luciano M Pompei
Role: STUDY_DIRECTOR
Faculdade de Medicina do ABC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistencia Materno Infantil Lambert
Santo André, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
41006620.0.0000.0082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.